admin – Page 5411 – Get News Story

Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

DelveInsight’s, “Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Toll-Like Receptor 4 (TLR-4) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Toll-Like Receptor 4 (TLR-4) Agonist Pipeline. Dive into DelveInsight’s comprehensive report today! @ Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Outlook

Key Takeaways from the Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Report

In August 2024:- Jonsson Comprehensive Cancer Center- The main purpose of this study is to evaluate the most effective immunotherapy vaccine components in patients with malignant glioma. Teh investigators previous phase I study (IRB #03-04-053) already confirmed that this vaccine procedure is safe in patients with malignant brain tumors, and with an indication of extended survival in several patients.
In July 2024:- Baylor College of Medicine- This study evaluates the efficacy, safety and immunogenicity of different formulations of the Na-GST-1 hookworm vaccine using a controlled human hookworm infection model in healthy, hookworm-naive adults.
DelveInsight’s Toll-Like Receptor 4 (TLR-4) Agonist pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Toll-Like Receptor 4 (TLR-4) Agonist treatment.
The leading Toll-Like Receptor 4 (TLR-4) Agonist Companies such as Eisai, Akaza Bioscience, OPNT-003, GeNeuro, MN-166 (ibudilast), Orexo, and others.
Promising Toll-Like Receptor 4 (TLR-4) Agonist Therapies such as P2PAR-100, SBT8230, RG 6115, TransCon TLR 7/8 agonist, NKTR-262, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Tilsotolimod, SD 101, Lefitolimod, Vesatolimod, Vidutolimod, Rintatolimod, DUET 01, NJB 834, INNA 051, Glycopyranosyl lipid adjuvant, G 100, TARA-002, RO 7020531, Resiquimod, BDC 1001, SHR 2150, LHC 165, PRX 034, ELI 002, IDX 9059, Entolimod, and others.

Stay ahead with the most recent pipeline outlook for Toll-Like Receptor 4 (TLR-4) Agonist. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Toll-Like Receptor 4 (TLR-4) Agonist Treatment Drugs

Toll-Like Receptor 4 (TLR-4) Agonist Emerging Drugs Profile

E-5564: Eisai

E-5564 (Eritoran) is a TLR (Toll-Like Receptor) 4 antagonist created with natural product organic synthesis technology. It is a structural analogue of Lipid A which is an activator of endotoxins of bacteria. It is expected to suppress inflammation and increasing in severity caused by COVID-19 by inhibiting the activation of TLR4, which is found in the most upstream position of various cytokine gene expression signaling that causes the cytokine-storm. Development is in collaboration with GCAR (Global Coalition for Adaptive Research).

It is currently in Phase III stage of development and is being developed by Eisai.

TAK-242: Akaza Bioscience

TAK-242 acts as inhibitor of Toll-like receptor 4. Akaza Bioscience is preparing to run a Phase II study of TAK-242, a novel immunological therapy. This pan-European study aims to investigate the safety and efficacy of TAK-242, as measured by changes in key biomarkers and 28-day survival rates. The trial will be a randomised, double-blind, placebo-controlled study in patients with Grade 1 or 2 ACLF.

Explore groundbreaking therapies and clinical trials in the Toll-Like Receptor 4 (TLR-4) Agonist Pipeline. Access DelveInsight’s detailed report now! @ New Toll-Like Receptor 4 (TLR-4) Agonist Drugs

Toll-Like Receptor 4 (TLR-4) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Infusion
Intradermal
Intramuscular
Intranasal
Intravaginal
Oral
Parenteral
Subcutaneous
Topical
Molecule Type

Toll-Like Receptor 4 (TLR-4) Agonist Products have been categorized under various Molecule types such as

Vaccines
Monoclonal Antibody
Peptides
Polymer
Small molecule
Product Type

Unveil the future of Toll-Like Receptor 4 (TLR-4) Agonist Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Toll-Like Receptor 4 (TLR-4) Agonist Market Drivers and Barriers

Scope of the Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Report

Coverage- Global
Toll-Like Receptor 4 (TLR-4) Agonist Companies- Eisai, Akaza Bioscience, OPNT-003, GeNeuro, MN-166 (ibudilast), Orexo, and others.
Toll-Like Receptor 4 (TLR-4) Agonist Therapies- P2PAR-100, SBT8230, RG 6115, TransCon TLR 7/8 agonist, NKTR-262, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Tilsotolimod, SD 101, Lefitolimod, Vesatolimod, Vidutolimod, Rintatolimod, DUET 01, NJB 834, INNA 051, Glycopyranosyl lipid adjuvant, G 100, TARA-002, RO 7020531, Resiquimod, BDC 1001, SHR 2150, LHC 165, PRX 034, ELI 002, IDX 9059, Entolimod, and others.
Toll-Like Receptor 4 (TLR-4) Agonist Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Toll-Like Receptor 4 (TLR-4) Agonist Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Toll-Like Receptor 4 (TLR-4) Agonist Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Toll-Like Receptor 4 (TLR-4) Agonist Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Toll-Like Receptor 4 (TLR-4) Agonist: Overview
Pipeline Therapeutics
Therapeutic Assessment
Toll-Like Receptor 4 (TLR-4) Agonist– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Toll-Like Receptor 4 (TLR-4) Agonist Collaboration Deals
Late Stage Products (Phase III)
E5564: Eisai
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TAK-242: Akaza Bioscience
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
OX125: Orexo
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Toll-Like Receptor 4 (TLR-4) Agonist Key Companies
Toll-Like Receptor 4 (TLR-4) Agonist Key Products
Toll-Like Receptor 4 (TLR-4) Agonist- Unmet Needs
Toll-Like Receptor 4 (TLR-4) Agonist- Market Drivers and Barriers
Toll-Like Receptor 4 (TLR-4) Agonist- Future Perspectives and Conclusion
Toll-Like Receptor 4 (TLR-4) Agonist Analyst Views
Toll-Like Receptor 4 (TLR-4) Agonist Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

The Global Synthetic Biology Market to Hit $59.91 Billion by 2029, More than $44 Billion Opportunities in the Next 6 Years – Arizton

“Synthetic Biology Market Research Report by Arizton”

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.

According to Arizton’s latest research report, the global synthetic biology market is growing at a CAGR of 25.68% during 2023-2029.

Looking for More Information? Click: https://www.arizton.com/market-reports/synthetic-biology-market

Report Scope:    

Market Size (2029): $59.91 Billion        

Market Size (2023): $15.20 Billion        

CAGR (2023-2029): 25.68%         

Historic Year:  2020-2022            

Base Year: 2023            

Forecast Year: 2024-2029            

Market Segmentation: Tool, Technology, Application, End-User, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa    

Book the Free Sample Now: https://www.arizton.com/market-reports/synthetic-biology-market

The global synthetic biology market is highly competitive, with major players like Agilent Technologies, Codexis, Eurofins Scientific, Illumina, Novozymes, and Thermo Fisher Scientific commanding significant market shares. These leading companies face intense competition from both emerging and established players, driving ongoing technological innovation and product development across sectors such as healthcare, industrial applications, food and beverages, agriculture, and environmental solutions.

To sustain their market position and expand their reach, key players are focusing on organic growth strategies. This includes launching new products, enhancing existing ones, and securing patents for innovative technologies. These strategies are bolstered by substantial investments in research and development (R&D), which lead to valuable collaborations and acquisitions that enhance their product offerings and market expertise.

Despite the strong presence of major companies, the synthetic biology market presents substantial growth opportunities for smaller and emerging players. These companies are actively developing advanced synthetic biology tools and technologies, contributing to the market’s dynamic nature and fostering new opportunities for innovation and market entry. The increasing global demand for advanced healthcare solutions and other applications particularly drives this growth.

Strategic Initiatives and New Collaborations in the Synthetic Biology Market

Novozymes and Codexis are actively pursuing strategic initiatives to bolster their market presence, including the launch of new products and fostering collaborative efforts. Similarly, Agilent Technologies and Eurofins Scientific are key players focusing on introducing new products in targeted regions to increase their global market share.

In 2023, Sumitomo Chemical and Ginkgo Bioworks launched a new initiative to utilize synthetic biology to produce functional chemicals, marking their third collaborative project. Since 2021, the two companies have worked together on biomanufacturing solutions for personal care, cosmetics, agriculture, and pharmaceuticals. Their latest project is aimed at enabling large-scale production of functional chemicals through fermentation.

Key Vendors

Agilent Technologies
Codexis
Eurofins Scientific
Illumina
Novozymes
Thermo Fisher Scientific
Amyris
ATUM
Bio-Rad Laboratories
Creative Biogene
Creative Enzymes
Cyrus Biotechnology
Editas Medicine
Genomatica
Genscript
Ginkgo Bioworks
Integrated DNA Technologies
LGC Biosearch Technologies
New England Biolabs
OriGene Technologies
Precigen
Sentebiolab
SynbiCITE
Synthego
Tessera Therapeutics
Viridos
Asimov
Twist Bioscience
Mammoth Biosciences
ElevateBio
Dupont
DSM
Bota Biosciences
Kiverdi
Merck KGaA
Synlogic
Huee
Upside Foods

Pharma and Biotech Companies Lead Growth in Global Synthetic Biology Market

Pharma and biotech companies are experiencing the highest growth in the global synthetic biology market. These industries have been instrumental in the early achievements of synthetic biology, primarily due to its close relationship with small-molecule drug production. Many of these drugs are derived from natural sources, making it relatively easy to adapt microbial production systems. Additionally, the modular nature of many biosynthetic pathways, especially those used in producing bioactive natural products like antibiotics, aligns well with synthetic biology’s engineering techniques. These pathways evolved for rapid diversification and cross-species compatibility and often feature large modular assembly lines, providing ideal opportunities for applying synthetic biology approaches.

Segmentation & Forecast

Tool

Oligonucleotides and Synthetic DNA
Enzymes
Cloning Technology Kits
Xeno-Nucleic Acids
Chassis Organisms

Technology

Enabling Technology
Enabled Technology

Application

Healthcare Application
Industrial Application
Food & Agriculture Application
Environmental Application

End-User

Academic/Research Institutes & Laboratories
Pharma & Biotech Companies
Others

North America Leads the Global Synthetic Biology Market with Strong R&D and Regulatory Support

North America dominates the global synthetic biology market, holding the largest share. The region features a vibrant synthetic biology sector, with over 530 regenerative medicine companies specializing in cell and gene therapy and stem cell-based treatments. These companies are at the forefront of research and development, leveraging synthetic biology to advance medical treatments. The US excels in conducting clinical trials of cell and gene therapy, with a rising number of patients opting for these innovative therapies. Frequent regulatory approvals in North America further bolster the region’s leadership in synthetic biology.

Geography

North America

The U.S.
Canada

Europe

Germany
The U.K.
France
Italy
Spain

APAC

Japan
China
India
Australia
South Korea

Latin America

Brazil
Mexico
Argentina

Middle East & Africa

Turkey
South Africa
Saudi Arabia

In a nutshell, the Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to gain a thorough understanding of the synthetic biology market. Request for Free Sample to get a glance at the report now: https://www.arizton.com/market-reports/synthetic-biology-market

What Key Findings Will Our Research Analysis Reveal?  

What are the key drivers of the global synthetic biology market?

How big is the global synthetic biology market?

Which region dominates the global synthetic biology market?

What is the growth rate of the global synthetic biology market?

Who are the major players in the global synthetic biology market?

Looking for Customization According to Your Business Requirement? https://www.arizton.com/customize-report/4490

Other Related Reports that Might be of Your Business Requirement  

Europe Cell And Gene Therapy Market – Focused Insights 2024-2029

The Europe cell and gene therapy market was valued at USD 2.26 billion in 2023 and is expected to reach USD 14.45 billion by 2029. Explore! https://www.arizton.com/market-reports/europe-cell-gene-therapy-market-size-analysis

Cell Counting Devices Market – Global Outlook & Forecast 2024-2029

The global cell counting devices market was valued at USD 12.39 billion in 2023 and is expected to reach USD 18.64 billion by 2029. Learn more about the market now: https://www.arizton.com/market-reports/cell-counting-devices-market

Why Arizton?                                             

100% Customer Satisfaction                                             

24×7 availability – we are always there when you need us                                             

200+ Fortune 500 Companies trust Arizton’s report                                             

80% of our reports are exclusive and first in the industry                                             

100% more data and analysis                                             

1500+ reports published till date                           

Post-Purchase Benefit                                         

1hr of free analyst discussion                                         
10% off on customization

About Us:                                                                                  

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                                

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                                 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                                       

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707                                      
Country: United States
Website: https://www.arizton.com/market-reports/synthetic-biology-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Global Synthetic Biology Market to Hit $59.91 Billion by 2029, More than $44 Billion Opportunities in the Next 6 Years – Arizton

Security Testing Market Growing Trends, Business Growth, Size, Future Scope, Segmentation, Dynamics and Forecast to 2029

“IBM (US), HCLTech (India), Synopsys (US), OpenText (UK), Cigniti (US), Qualitest (UK), Intertek (UK), DXC Technology (US), eInfochips (US), Checkmarx (US), HackerOne (US), Invicti (US), DataArt (US), Cobalt Labs (US), Trustwave (US), Contrast Security (US), Veracode (US), Qualys (US), OffSec (US).”

Security Testing Market by Type (Network, Application, Device, Social Engineering), Network Security Testing (Penetration Testing, Vulnerability Scanning, Firewall), Application Testing Tools (RASP, SAST, DAST, IAST) – Global Forecast to 2029.

The global security testing market size is projected to grow from USD 14.5 billion in 2024 to USD 43.9 billion by 2029 at a Compound Annual Growth Rate (CAGR) of 24.7% during the forecast period. The sophistication and frequency of cyberattacks are rising, forcing enterprises to proactively detect and address vulnerabilities, which is driving the expansion of security testing. In addition, frequent security testing must ensure compliance and protect sensitive data due to strict regulatory requirements such as GDPR, HIPAA, and PCI DSS further fuels the market growth.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150407261

Based on the application testing tools, SAST accounts for the highest market size during the forecast period.

The adoption of Static Application Security Testing (SAST) tools is increasing as organizations prioritize secure software development. SAST tools enable developers to identify and fix security vulnerabilities early in the coding process, reducing the risk of security flaws in production. This shift is driven by the growing emphasis on integrating security into the software development lifecycle (SDLC) and the need to comply with stringent security standards. As a result, more companies are adopting SAST tools to enhance code security, improve development efficiency, and ensure that applications are robust against cyber threats from the outset.

By Application security testing type, web application security testing accounts for the highest market size during the forecast period.

The adoption of web application security testing is growing as organizations increasingly rely on web-based platforms for business operations and customer interactions. With the rise in cyber threats targeting web applications, such as SQL injection and cross-site scripting (XSS), companies are prioritizing security testing to identify and mitigate vulnerabilities before they can be exploited. This proactive approach is driven by the need to protect sensitive data, ensure compliance with regulations, and maintain customer trust in an environment where web applications are a critical part of the business landscape.

By Region, Asia Pacific will grow at the highest CAGR during the forecast period.

The adoption of security testing services in the Asia Pacific region is rapidly increasing due to the region’s expanding digital economy and the rising threat of cyberattacks. As busin

esses in Asia-Pacific embrace digital transformation and cloud computing, the need to identify and address vulnerabilities in their systems has become crucial. Regulatory pressures and growing awareness of cybersecurity risks are also driving organizations to invest in security testing solutions to ensure the resilience of their IT infrastructure and protect sensitive data from breaches. This trend is further fueled by the region’s diverse and complex threat landscape, prompting a proactive approach to cybersecurity.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=150407261

Unique Features in the Security Testing Market

One unique feature driving the security testing market is the increasing sophistication and frequency of cyberattacks. As cybercriminals adopt advanced tactics, enterprises are compelled to implement security testing solutions that proactively identify and address vulnerabilities before they can be exploited.

Regulatory Compliance as a Growth Driver Another distinctive aspect of the security testing market is the strong influence of regulatory compliance requirements. Organizations must adhere to stringent standards such as GDPR, HIPAA, and PCI DSS to protect sensitive data and maintain customer trust.

Adoption of Automation and AI in Testing The growing adoption of automation, artificial intelligence (AI), and machine learning (ML) technologies is a unique trend in the security testing market. These technologies enable faster, more efficient, and accurate identification of vulnerabilities across complex IT environments.

Cloud-Based Security Testing Solutions Another unique feature is the shift toward cloud-based security testing solutions. As organizations increasingly migrate to cloud environments, the demand for security testing tools designed specifically for cloud infrastructures is on the rise.

Increased Focus on Application Security Lastly, the focus on application security is a notable feature in the market. With the rapid growth of web and mobile applications, ensuring the security of these applications has become a critical priority for businesses.

Major Highlights of the Security Testing Market

Rising Need for Proactive Vulnerability Detection Another key highlight is the growing need for proactive vulnerability detection. As cyberattacks become more frequent and complex, businesses are prioritizing the identification and mitigation of security flaws before they can be exploited.

Regulatory Compliance Driving Market Expansion A major driving force in the market is regulatory compliance. Stringent standards such as GDPR, HIPAA, and PCI DSS require organizations to implement regular security testing to ensure the protection of sensitive data and avoid penalties.

Increasing Adoption of AI and Automation The increasing integration of artificial intelligence (AI) and automation in security testing is another notable highlight. These technologies enhance the efficiency and accuracy of testing processes by enabling automated vulnerability detection, continuous monitoring, and predictive analysis.

Growth in Cloud-Based Security Solutions The market is also witnessing a significant shift toward cloud-based security testing solutions. With more organizations migrating to cloud infrastructures, the demand for security tools specifically designed for cloud environments has surged.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=150407261

Top Companies in the Security Testing Market

The security testing market is led by some of the globally established players, such as IBM (US), HCLTech (India), Synopsys (US), OpenText (UK), Cigniti (US), Qualitest (UK), Intertek (UK), DXC Technology (US), eInfochips (US), Checkmarx (US), HackerOne (US), Invicti (US), DataArt (US), Cobalt Labs (US), Trustwave (US), Contrast Security (US), Veracode (US), Qualys (US), OffSec (US), NCC Group (UK), GitHub (US), Bugcrowd (US), Applause (US), Rapid7 (US), and Parasoft (US). Partnerships, agreements, collaborations, acquisitions, and product developments are various growth strategies these players use to increase their market presence.

IBM (US) is a computer, technology, and IT consulting corporation. The company operates through various segments, such as cognitive solutions, global business services, technology services and cloud platforms, systems, and global financing. IBM’s clients comprise individual users, specialized businesses, and institutions, such as government, IT, defense, and educational organizations. In the category of security testing services, IBM offers X-Force Red Penetration Testing Services, X-Force Red Social Engineering Services, and X-Force Red Offensive Security Services. With the geographic presence across North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America, the company caters to various industries, such as IT, healthcare, life sciences, government, telecom, automobile, manufacturing, chemicals and petroleum, electronics, energy and power, media and entertainment, mining, retail, BFSI, travel and transportation, education, and others.

Synopsys (Canada) provides advanced technologies for chip design, verification, IP integration, and software security and quality testing. The company’s security IP solutions segment includes a range of cryptography cores, security protocol accelerators and processors, embedded security IP modules, secure boot and cryptography middleware as well as content protection IP for integration into system-on-chips. These IP solutions also provide the highest levels of security for a range of products in the mobile, automotive, digital home, lot, and cloud computing markets. These integrated solutions enable the most efficient silicon design and the highest level of security to help prevent a wide range of evolving threats in connected devices. For security testing, Synopsys provides software tools such as Polaris, an AppSec which is used from development to deployment; Coverity which find security and quality defects in code; Seeker which automates web application security testing in DevOps; as well as Static Application Security Testing (SAST); Interactive Application Security Testing (IAST); and Defensics Fuzz Testing. It also provides services such as penetration testing services, MAST and others. With more than 30 years of experience, Synopsys has more than 14,000 employees and is present across North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103
City: Delray Beach
State: FL 33445
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/security-testing-market-150407261.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Security Testing Market Growing Trends, Business Growth, Size, Future Scope, Segmentation, Dynamics and Forecast to 2029

Atopic Dermatitis Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

DelveInsight’s, “Atopic Dermatitis Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Atopic Dermatitis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Atopic Dermatitis Pipeline Outlook

Key Takeaways from the Atopic Dermatitis Pipeline Report

In September 2024:- Aclaris Therapeutics Inc.- A Phase 2a Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of ATI-2138 Administered Over 12 Weeks in Participants With Moderate to Severe Atopic Dermatitis.
In September 2024:- Incyte Corporation- This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
DelveInsight’s Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Atopic Dermatitis treatment.
The leading Atopic Dermatitis Companies such as Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 Therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
Promising Atopic Dermatitis Therapies such as Dupilumab, APG777, ATI-2138, GSK1070806, HY209GEL, ADX-914, Rocatinlimab, TAVO101, and others.

Stay ahead with the most recent pipeline outlook for Atopic Dermatitis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Atopic Dermatitis Treatment Drugs

Atopic Dermatitis Emerging Drugs Profile

Tapinarof: Dermavant Sciences

Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) that binds and activates the aryl hydrocarbon receptor in multiple cell types, including cells of the target tissue-human skin. Tapinarof has also shown to moderate proinflammatory cytokine expression in stimulated peripheral blood CD4+ T cells and ex vivo human skin, and impact barrier gene expression in primary human keratinocytes. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Atopic dermatitis.

Etrasimod: Pfizer

Etrasimod is an oral, once daily, selective sphingosine-1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. In addition to UC, it is being investigated for a range of other immuno-inflammatory diseases and is in Phase II/III stage of development for the treatment of patients with Atopic dermatitis.

B244: AOBiome

AOBiome’s B244 is a patented, proprietary, topical formulation incorporating a single strain of beneficial ammonia-oxidizing bacteria (AOB), Nitrosomonas eutropha D23. B244 is designed to repopulate the skin microbiome with AOBs normally found on the body but frequently stripped away by most soaps. Once deployed on the skin, B244 converts ammonia to nitrite, known to have antibacterial properties, and to nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. The drug is currently being evaluated in Phase II stage of development for the treatment of patients with Atopic dermatitis.

Lirentelimab: Allakos Inc.

Lirentelimab (AK002) is an afucosylated, humanized IgG1 monoclonal antibody which activates the inhibitory receptor Siglec-8. Additionally, Lirentelimab depletes eosinophils via antibody dependent cellular cytotoxicity (ADCC) in blood. Siglec-8 is a member of the family of cell surface receptors called Sialic acid-binding immunoglobulin-type lectins (Siglecs). Allakos initiated a Phase II trial evaluating subcutaneous Lirentelimab versus placebo in patients with atopic dermatitis. Results from this trial are expected in the second half of 2023.

QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

QY201 acts on Jak1/Tyk2 dual targets with higher activity and selectivity, which is significantly superior to the similar drugs. QY201 is an innovative drug for the treatment of atopic dermatitis. QY201 was independently developed by E-nitiate with global patents, is undergoing Phase I/II clinical trial for atopic dermatitis.

Explore groundbreaking therapies and clinical trials in the Atopic Dermatitis Pipeline. Access DelveInsight’s detailed report now! @ New Atopic Dermatitis Drugs

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Atopic Dermatitis Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Atopic Dermatitis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Atopic Dermatitis Market Drivers and Barriers

Scope of the Atopic Dermatitis Pipeline Report

Coverage- Global
Atopic Dermatitis Companies- Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 Therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
Atopic Dermatitis Therapies- Dupilumab, APG777, ATI-2138, GSK1070806, HY209GEL, ADX-914, Rocatinlimab, TAVO101, and others.
Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Atopic Dermatitis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Atopic Dermatitis Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Atopic Dermatitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Atopic Dermatitis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Tapinarof: Dermavant Sciences
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
B244: AOBiome
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
EP262: Escient Pharmaceuticals
Drug profiles in the detailed report…..
Inactive Products
Atopic Dermatitis Key Companies
Atopic Dermatitis Key Products
Atopic Dermatitis- Unmet Needs
Atopic Dermatitis- Market Drivers and Barriers
Atopic Dermatitis- Future Perspectives and Conclusion
Atopic Dermatitis Analyst Views
Atopic Dermatitis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atopic Dermatitis Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

Stocks Driving Market Momentum with Groundbreaking Contracts and Technologies: LUNR, PRSO, LPTH, INBS, PNPN.V

Groundbreaking contracts and technological advancements across space exploration, environmental monitoring, high-grade mineral discovery, military and healthcare solutions, these five companies are setting the stage for significant market growth. Take a look now!

NASA has awarded Intuitive Machines (Nasdaq: LUNR) a Near Space Network contract valued at $4.82 billion to provide communication and navigation services from Earth’s surface to beyond the Moon. The 10-year contract, starting in October 2024, supports NASA’s Artemis campaign and includes the launch of Intuitive Machines’ lunar satellite constellation to enhance data transmission and autonomous operations. This contract solidifies Intuitive Machines’ leadership in space communications and bolsters its vision to commercialize lunar activities, creating new infrastructure for the lunar economy.

Peraso Inc. (NASDAQ: PRSO) has secured a key purchase order for its Perspectus module, leveraging advanced 60 GHz mmWave technology for military battlefield applications. The system enhances communication and situational awareness for soldiers through narrow-beamforming technology, reducing detection risk and interference. Equipped with power-saving features, the modules can operate continuously for up to a week on a single battery charge. With 40 granted patents and a strong innovation pipeline, Peraso is positioned as a leader in high-performance military and wireless communications technology. The stock closed flat on 7x its average 60-day volume, making it a stock to watch closely in the near term.

LightPath Technologies (NASDAQ: LPTH) has launched its next-gen Mantis™ camera, targeting the $500M furnace monitring market. Designed for power plants, the camera optimizes burn processes, enhances safety, and supports environmental compliance by reducing CO2 emissions, while supporting compliance with stringent environmental regulations in the U.S. and Europe. This marks LightPath’s shift toward advanced product solutions, with its first commercial order secured in the southeastern U.S.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares surged this week, climbing 24% to $2.48 from Friday’s September 13, 2024 close of $2, following the release of promising financial data. The company reported preliminary unaudited sales figures of $0.73 million and $3.11 million for the fiscal year ending June 30, 2024. Additionally, INBS expects a 20% increase in cartridge sales and a 26% rise in reader sales compared to the previous year.

Power Nickel Inc. (TSX.V: PNPN) (OTCQB: PNPNF) has made a breakthrough at its Lion Zone discovery, with 10 out of 12 drill holes intercepting high-grade sulphide mineralization, significantly expanding the zone both laterally and vertically by 150 meters. With a fully funded 30,000-meter winter drill program set to capitalize on these results, Power Nickel is positioning itself for a world-class polymetallic discovery. As CEO Terry Lynch stated, this could be a company-defining moment, making now the ideal time for investors to get in on this rapidly growing opportunity. Power Nickel stock has experienced a surge in trading volume across both U.S. and Canadian markets, posting gains of approximately 23% on the TSX Venture and 24% on the OTCQB, significantly boosting shareholder value.

Intuitive Machines (Nasdaq: LUNR) lands a landmark contract, valued at up to $4.82 billion, Starting in October 2024. Meanwhile, companies like LightPath Technologies (NASDAQ: LPTH), Power Nickel (TSX.V: PNPN)(OTCQB: PNPNF), Peraso Inc. (NASDAQ: PRSO), and Intelligent Bio Solutions (NASDAQ: INBS) are making major strides in their respective fields, driving innovation and boosting investor interest.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Stocks Driving Market Momentum with Groundbreaking Contracts and Technologies: LUNR, PRSO, LPTH, INBS, PNPN.V

B-Cell Lymphomas Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

DelveInsight’s, “B-Cell Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 160+ companies and 170+ pipeline drugs in B-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the B-Cell Lymphomas Pipeline. Dive into DelveInsight’s comprehensive report today! @ B-Cell Lymphomas Pipeline Outlook

Key Takeaways from the B-Cell Lymphomas Pipeline Report

In September 2024:- Pfizer- The purpose of this study is to learn about the effects of three study medicines [maplirpacept (PF-07901801), tafasitamab, and lenalidomide] when given together for the treatment of diffuse large B-cell lymphoma (DLBCL).
In September 2024:- Genmab- The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.
DelveInsight’s B-Cell Lymphomas pipeline report depicts a robust space with 160+ active players working to develop 170+ pipeline therapies for B-Cell Lymphomas treatment.
The leading B-Cell Lymphomas Companies such as Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co, and others.
Promising B-Cell Lymphomas Therapies such as Selinexor, Rituximab, Cyclophosphamide, ME-401, and others.

Stay ahead with the most recent pipeline outlook for B-Cell Lymphomas. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ B-Cell Lymphomas Treatment Drugs

B-Cell Lymphoma Emerging Drugs

Odronextamab: ZAI Lab

Odronextamab is a human IgG4-based bispecific antibody that binds to CD3, a T-cell antigen associated with the T-cell receptor complex, and CD20, a B-cell surface antigen present on normal B cells and several B cell lineage malignancies. Odronextamab is currently being studied in a potentially pivotal Phase 2 study in B-cell non-Hodgkin lymphoma (B-NHL), including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL). In April 2020, Zai Lab obtained exclusive rights to develop and commercialize odronextamab in greater China from Regeneron Pharmaceuticals.

NKTR-255: Nektar Therapeutics

NKTR-255 is a biologic that targets the IL-15 pathway in order to activate the body’s innate and adaptive immunity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular cytotoxicity molecules as well as to enhance CAR-T therapies. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Relapsed/Refractory Large B-cell Lymphoma.

Zilovertamab Vedotin: Merck Sharp & Dohme LLC

Zilovertamab vedotin is under development for the treatment of solid tumors, blood cancer including advanced or metastatic urothelial carcinoma of renal pelvis, ureter (upper urinary tract), bladder, or urethra, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, triple-negative breast cancer (TNBC), diffuse large B-cell lymphoma, or Richter transformation lymphoma. It is administered through intravenous route of administration. It acts by targeting ROR1 antigens expressing cells. The drug candidate is linked to UC-961-linker-monomethyl auristatin E (MMAE) ADC that preserves the high-affinity binding and specificity of UC-961 and allows for ROR1-targeted intracellular release of MMAE. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Abexinostat: Xynomic Pharmaceuticals

Abexinostat (PCI-24781) is under development for the treatment of metastatic renal cell carcinoma, follicular lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, relapsed and refractory mantle cell lymphoma. It is formulated as a capsule and is administered through oral route. It acts by targeting histone deacetylase (HDAC). It was also under development for the treatment of lung cancer, colon cancer, gastric cancer, metastatic colorectal cancer, pancreatic cancer, nasopharyngeal cancer, haematological malignancies such as follicular non-Hodgkin lymphoma, and chronic lymphocytic leukemia (CLL) as second line of therapy, refractory and relapsed multiple myeloma as first and second line of therapy, refractory and relapsed acute myeloid leukemia, acute lymphoblastic leukemia, high or intermediary-2 risk myelodysplastic syndrome and sarcomas as second line of therapy, fallopian tube cancer, peritoneal cancer, brain tumor and neuroblastoma. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Diffuse Large B-cell Lymphoma.

Explore groundbreaking therapies and clinical trials in the B-Cell Lymphomas Pipeline. Access DelveInsight’s detailed report now! @ New B-Cell Lymphomas Drugs

B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Parenteral
intravenous
Subcutaneous
Topical

B-Cell Lymphomas Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Unveil the future of B-Cell Lymphomas Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ B-Cell Lymphomas Market Drivers and Barriers

Scope of the B-Cell Lymphomas Pipeline Report

Coverage- Global
B-Cell Lymphomas Companies- Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co, and others.
B-Cell Lymphomas Therapies- Selinexor, Rituximab, Cyclophosphamide, ME-401, and others.
B-Cell Lymphomas Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
B-Cell Lymphomas Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on B-Cell Lymphomas Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ B-Cell Lymphomas Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
B-Cell Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
B-Cell Lymphoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Odronextamab: ZAI Lab
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Abexinostat: Xynomic Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
TG 1801: TG Therapeutics Inc.
Drug profiles in the detailed report…..
Inactive Products
B-Cell Lymphoma Key Companies
B-Cell Lymphoma Key Products
B-Cell Lymphoma- Unmet Needs
B-Cell Lymphoma- Market Drivers and Barriers
B-Cell Lymphoma- Future Perspectives and Conclusion
B-Cell Lymphoma Analyst Views
B-Cell Lymphoma Key Companies
Appendix

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: B-Cell Lymphomas Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

Temecula Wine Tours Offers Custom Wine Tasting Experiences in Southern California

Limo Bus Wine Tours is excited to announce its customized wine-tasting tours, offering visitors a unique opportunity to experience the best of Temecula’s renowned wine country. These luxury tours provide a memorable way to explore Southern California’s premier wine region in style and comfort.

Limo Bus Wine Tours presents an all-inclusive experience, allowing guests to enjoy the beautiful Temecula Valley vineyards while indulging in fine wine tastings. Whether planning a special occasion or simply looking for a relaxing day, Limo Bus Wine Tours offers tailored experiences to meet individual needs.

Premier Wine Country Experience

Temecula Wine Tours provides guests with a journey through some of the finest wineries in the region. The tour includes guided tastings, educational insights into the winemaking process, and an exploration of Temecula’s rich wine history. The stunning vineyards and exquisite wines make for an unforgettable experience.

Luxurious Transportation

Guests can travel in style aboard Limo Bus Wine Tours’ fleet of party buses, limousines, and SUVs. With professional chauffeurs guiding the way, visitors can sit back, relax, and fully embrace the breathtaking views of the valley. For a more immersive experience, guests can opt for open-air or cable car wine tours, offering unobstructed views of the picturesque vineyards.

Customizable Tour Packages

Temecula Wine Tours caters to all kinds of events, including bachelorette parties, weddings, and corporate gatherings. Private tours are available and can be fully customized to meet the specific needs and preferences of each group. Each tour includes transportation, tasting fees, and expert guides, ensuring a seamless and enjoyable experience from start to finish.

All-Inclusive Wine Tasting Packages

Limo Bus Wine Tours prides itself on offering comprehensive wine-tasting experiences. Their knowledgeable guides are experts in Temecula’s wine scene, providing guests with an in-depth understanding of the region’s unique offerings. From transportation to tasting fees, all aspects of the tour are covered, allowing guests to focus on enjoying their time in the valley.

For those looking to experience Temecula’s wine country in an exclusive, personalized way, Limo Bus Wine Tours offers group tours and private wine-tasting adventures that cater to both small and large parties.

To learn more about the tours or to make a reservation, visit https://limobuswinetour.com/

About Limo Bus Wine Tours

Limo Bus Wine Tours is a premier wine tour operator based in Temecula, California, offering luxury wine-tasting experiences in the heart of Temecula Valley. With customizable tour options, luxurious transportation, and expert guides, Limo Bus Wine Tours provides guests with an unforgettable journey through Southern California’s top wineries.

Media Contact
Company Name: Limo Bus Wine Tours
Contact Person: Brayam Rodriguez
Email: Send Email
City: Temecula
State: California
Country: United States
Website: https://limobuswinetour.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Temecula Wine Tours Offers Custom Wine Tasting Experiences in Southern California

Natural Disaster Detection IoT Market Growth Outlook, Size, Share, Driving Factors, Future Demand, Key Segments and Forecast to 2027

“SAP (Germany), Sony (Japan), Nokia (Finland), Sadeem Technology (Saudi Arabia), Lumineye (US), Venti LLC (US), SimpliSafe (India), One Concern (US), OnSolve (US), Trinity Mobility (India), SkyAlert (Mexico), Serinus (Germany), Knowx Innovations (India).”

Natural Disaster Detection IoT Market by Component (Hardware, Solutions, Services), Application (Flood Detection, Drought Detection), Communication System (First Responder Tools, Vehicle-ready Gateways), End User and Region – Global Forecast to 2027.

The natural disaster detection IoT market is projected to grow from USD 0.3 billion in 2022 to USD 1.7 billion by 2027, with a compound annual growth rate (CAGR) of 36.0% during the forecast period. The market’s expansion is being fueled by the increasing use of IoT devices and sensors for disaster prediction and early detection.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164607105

Professional services segment is estimated to lead the natural disaster detection IoT market in 2022

Professional services offer optimization services and customized services and ensure operational proficiency, design support, solution validation, and knowledge management. Professional services include consulting, deployment and integration, support and maintenance, and training and simulation.

First Responder Tools segment is expected to have a higher growth rate during the forecast period

To benefit First Responders (FRs) with the latest technologies such as IoT, AI, and smart devices are offered to FRs and rescuers to create a safer, more efficient, and technologically advanced operating framework. Proposals are made covering the topics such as sense augmentation, precise positioning, cognitive support, multi-sense XR interfaces, and robust communications. Tools using technologies such as wearable technologies, training tools and applications, devices and tools to enhance human sensing, cognitive load management, situational awareness, operating teams’ management, robust communications in adverse environments, technologies for victim detection, tools to enhance safety and efficiency of FRs, and cognitive load management are applied.

Government Organizations segment is set to emerge as a larger market during the forecast period

The government was using conventional technologies for emergency planning. IoT provides more efficient solutions when it comes to disaster management, and this can transform emergency planning. IoT in disaster management can help governments improve evacuation systems and relief mechanisms. Government organizations around the globe are expected to use IoT in disaster management systems for better planning and minimizing losses.

Asia Pacific is projected to grow at the fastest growth rate during the forecast period

Asia Pacific consists of countries, such as Japan, China, India, Australia, and New Zealand. The countries in Asia Pacific region are projected to register high growth rates in the natural disaster detection IoT market. The region is expected to witness the highest CAGR during the forecast period. Countries such as China and Japan are taking several initiatives to deploy natural disaster detection IoT solutions.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=164607105

Unique Features in the Natural Disaster Detection IoT Market

This growth reflects the rising demand for advanced technological solutions to predict and mitigate the impact of natural disasters, highlighting the critical role of IoT in this area.

Real-Time Disaster Prediction and Monitoring One of the most distinctive features of this market is the ability of IoT devices and sensors to provide real-time disaster prediction and monitoring. These systems can detect early warning signs of natural disasters such as earthquakes, floods, and wildfires, enabling timely alerts and responses.

Wide Range of IoT Devices and Sensors The natural disaster detection IoT market is characterized by the diverse range of IoT devices and sensors it employs. From seismometers for detecting earthquakes to hydrological sensors for monitoring water levels and temperature sensors for identifying wildfires, these devices are tailored to specific types of disasters.

Growing Adoption in Smart Cities and Infrastructure Another unique feature is the increasing adoption of IoT-based disaster detection solutions in smart cities and infrastructure projects. As cities become more connected, there is a growing emphasis on integrating disaster prediction systems into urban planning and infrastructure management.

Use of Artificial Intelligence (AI) and Machine Learning (ML) The incorporation of AI and machine learning into IoT disaster detection systems is another notable feature. AI and ML algorithms analyze large datasets collected from IoT sensors to identify patterns and predict potential disasters with greater accuracy.

Major Highlights of the Natural Disaster Detection IoT Market

This impressive growth underscores the increasing reliance on IoT technologies for disaster prediction and management, driven by the rising frequency and intensity of natural disasters worldwide.

Increased Use of IoT for Disaster Prediction The growing adoption of IoT devices and sensors for real-time disaster prediction is another key highlight. IoT technologies enable early detection of natural disasters such as earthquakes, floods, and wildfires, providing timely warnings that allow for faster, more efficient responses.

Integration with AI and Data Analytics The integration of IoT with artificial intelligence (AI) and data analytics is a standout feature in the market. IoT sensors generate vast amounts of data that, when processed using AI and machine learning algorithms, improve the accuracy and speed of disaster forecasting.

Growing Adoption in Smart Cities and Urban Planning The adoption of IoT-based disaster detection systems in smart cities and urban infrastructure is another highlight of the market. As cities become more connected, there is a growing focus on using IoT technologies to monitor environmental factors and ensure disaster readiness.

Cloud-Based IoT Platforms for Scalable Solutions The rising demand for cloud-based IoT platforms in disaster detection is another key highlight. These platforms allow for scalable, real-time data collection and analysis across various regions, offering centralized management of disaster detection efforts.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=164607105

Top Companies in the Natural Disaster Detection IoT Market

The major vendors covered in the natural disaster detection IoT market are The major players in the natural disaster detection IoT market are NEC Corporation (Japan), BlackBerry (Canada), Semtech (US), SAP (Germany), Sony (Japan), Nokia (Finland), Sadeem Technology (Saudi Arabia), Lumineye (US), Venti LLC (US), SimpliSafe (India), One Concern (US), OnSolve (US), Trinity Mobility (India), SkyAlert (Mexico), Serinus (Germany), Knowx Innovations (India), OgoXe (France), Aplicaciones Tecnológicas SA (Spain), Earth Networks (US), Responscity Systems (India), Sensoterra (Netherlands), Intel (US), Grillo (Brazil), Bulfro Monitech (India), and Green Stream Technologies (US). These players have adopted various growth strategies, such as partnerships, business expansions, agreements, and collaborations, new product launches, to expand their presence in the natural disaster detection IoT market.

NEC Corporation engages in the computing and communications applications of systems, components, services, and integrated solutions. It operates through the following segments: Public Business, Enterprise Business, System Platform Business, Telecom Carrier Business, and Others. The Public Business segment provides outsourcing and cloud services, system integration, system architecture and consulting support, and system equipment for medical, public, and financial institutions. The information technology solutions are offered by the Enterprise Business segment for manufacturing, retail, and services. The equipment to telecom carriers is supplied by the telecom carrier business segment for network implementation, network control platform, and operating services. The System Platform Business deals with businesses such as terminals to network and computer equipment, software products, and service platforms. The Others segment includes smart energy solutions, mobile phones, and lighting equipment businesses.

BlackBerry is a leader in cybersecurity—helping businesses, government agencies, and safety-critical institutions using IoT. BlackBerry products and services include the Cylance, BlackBerry UEM management platform, the BlackBerry AtHoc critical event management solution, and BlackBerry QNX software for secure embedded systems. The company provides intelligent security software and services to enterprises and governments around the world. It is based in Waterloo, Ontario, and leverages AI and ML to deliver innovative solutions in the areas of cybersecurity, safety, and data privacy.

Semtech (US) : Semtech Corporation, based in the United States, is a leading provider of analog and mixed-signal semiconductor products and advanced algorithms. Founded in 1960, Semtech has established itself as an innovator in technology solutions for various industries, including communications, industrial, and consumer markets.

SAP (Germany) : SAP, headquartered in Walldorf, Germany, is a global leader in enterprise software solutions. Founded in 1972, SAP has grown to become one of the largest software companies in the world, serving businesses of all sizes and industries. SAP’s flagship product is its Enterprise Resource Planning (ERP) software, which helps organizations manage key business functions such as finance, human resources, procurement, and supply chain operations. The company also offers a wide range of other software solutions, including customer relationship management (CRM), business intelligence, and analytics.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Natural Disaster Detection IoT Market Growth Outlook, Size, Share, Driving Factors, Future Demand, Key Segments and Forecast to 2027

STOCKROOM Hong Kong Brings Home Comfort And New Experience with New Range of Stylish and Affordable Sofas

STOCKROOM Hong Kong, the premier online destination for contemporary furniture, introduces a new collection of fabric and leather sofas, providing quality and style at unbeatable prices.

STOCKROOM, a leading online furniture retailer in Hong Kong, is thrilled to unveil its latest collection of stylish and affordable sofas, designed to transform houses into stylish and inviting homes. Known for sourcing high-quality furniture from around the globe, STOCKROOM bypasses the middleman, making designer furniture accessible to a wider audience without compromising on quality or style. Their new sofa collection perfectly embodies this commitment to providing exceptional quality, design, and value.

Finding the perfect sofa is often the key to creating a comfortable and inviting living space where families and friends can relax and unwind. STOCKROOM Hong Kong understands this and has meticulously curated a collection of sofas that caters to a wide range of tastes, needs, and preferences. Whether you envision a cozy fabric sofa ideal for movie nights or a sleek leather sofa to complement a modern aesthetic, STOCKROOM’s diverse selection ensures a perfect match for every home and lifestyle.

STOCKROOM

For those who appreciate the warmth, versatility, and comfort of fabric, STOCKROOM’s range of fabric sofas in Hong Kong offers a delightful array of options. From plush velvet to durable linen and everything in between, the collection features a beautiful spectrum of fabrics, textures, and colors to suit every taste and blend seamlessly with any interior design scheme. Each fabric sofa is carefully crafted with meticulous attention to detail, ensuring both durability and long-lasting comfort that can be enjoyed for years to come.

For those who gravitate towards a touch of luxury and sophistication, STOCKROOM’s leather sofas in Hong Kong are a perfect choice. These sofas, crafted from high-quality, ethically-sourced leather, exude elegance and sophistication, adding a touch of timeless style to any living space. The leather sofas are available in various configurations, sizes, and colors, allowing customers to find the perfect fit for their living room dimensions and personal style.

STOCKROOM’s commitment to quality is unwavering. They work directly with the best manufacturers around the world, ensuring that every sofa meets their stringent quality standards. This direct partnership allows STOCKROOM to offer their furniture at incredibly competitive prices, making luxury and style more attainable than ever before for discerning homeowners in Hong Kong.

By offering an extensive range of fabric and leather sofas at affordable prices, STOCKROOM is making stylish and comfortable living spaces achievable for everyone in Hong Kong, demonstrating their core belief that everyone deserves a beautiful and inviting home.

About STOCKROOM

STOCKROOM is an online furniture shop based in Hong Kong dedicated to providing high-quality, contemporary furniture at accessible prices. They source their products directly from the best manufacturers worldwide, eliminating costly middlemen and offering exceptional value to their customers.

Media Contact
Company Name: STOCKROOM
Contact Person: Jojoba
Email: Send Email
Phone: +852 2817 0999
Country: HongKong
Website: http://www.stockroom.com.hk/

Vijilan Partners with Corelight to Enhance Security for MSPs, MSSPs, and Enterprises

AVENTURA, Fla. – Sept. 18, 2024 – Vijilan Security, a leading Managed Security Service Provider (MSSP), today announced that it is entering into a partnership with Corelight, a pioneer in Network Detection and Response (NDR) technology. The collaboration aims to enhance security services for Managed Service Providers (MSPs), MSSPs, and enterprises by addressing the critical challenge of detecting and responding to network-based threats across all assets, including networks, devices, users, applications, data, and cloud services.

Revolutionizing MDR with Advanced Network Security

Vijilan has joined Corelight’s Apex DefeNDR program and will incorporate Corelight’s Open NDR platform into its offerings. The goal is to revolutionize the way MSPs and MSSPs analyze comprehensive, correlated network data to protect their clients’ environments. Many Managed Detection and Response (MDR) providers claim to manage detection and response across all assets, but when pressed, their scope turns out to be limited just to endpoints. Rather, true MDR should provide visibility across all critical assets, including networks, devices, applications, data, identity, and cloud services.

Corelight transforms network and cloud activity into evidence so that data-first defenders can stay ahead of ever-changing attacks. Delivered by its Open NDR Platform, Corelight’s comprehensive, correlated evidence gives customers unparalleled visibility into their networks. This evidence allows security analysts to unlock new analytics, investigate faster, hunt like an expert, and even disrupt future attacks. This ensures MSPs, MSSPs, and their clients receive the complete protection they expect from a robust security solution.

Enhanced Security with Corelight’s Open NDR Technology

Traditional perimeter-based security measures, such as Intrustion Detection Systems (IDS), are proving themselves to be no longer sufficient to protect against sophisticated cyber threats. Network Detection and Response (NDR) is therefore a crucial component of a modern security stack, providing deep visibility into network traffic to identify malicious activities that evade traditional security controls. By focusing on the comprehensive analysis of network traffic, Corelight’s Open NDR Platform helps detect advanced and emerging threats, including those already inside the network, enabling faster response times and reducing the risk of data breaches.

To this end, Vijilan’s integration of Corelight Open NDR technology strengthens its ability to detect, analyze, and respond to a wide range of network-based threats. Corelight’s platform, built on the powerful, open source Zeek (formerly Bro) network security monitoring framework and Suricata IDS, offers unmatched visibility into network activity, allowing security teams to identify subtle indicators of compromise (IoCs) and take immediate action.

According to Kevin Nejad, CEO of Vijilan Security, “Analyzing every packet that traverses the network, whether malicious or not, is not something most technologies can do. I have been a big fan of Zeek/Bro for more than two decades, but the enterprise version with great support wasn’t available until Corelight brought it to life. Now, MSPs and small to medium-sized businesses have access to enterprise-grade products that were previously out of reach.”

Nejad added, “This partnership goes beyond solving today’s problems. Corelight’s forward-thinking approach to managing the increasing volume of new traffic today and in the future sets them apart. We value this partnership and are excited to help stop security breaches and assist our partners in regulated industries, finance, healthcare, manufacturing, DoD, and government to meet all their security compliance requirements.”

Corelight’s Data-Centric Approach

Corelight’s data-centric approach ensures that security operations are informed by high-fidelity data streams that are both contextual and reliable. This enables security analysts to conduct more effective threat hunting and incident response, relying on the integrity and depth of the data provided by Corelight. By transforming raw network traffic into actionable insights, Corelight empowers organizations to make informed decisions that strengthen their security posture.

Key benefits of the partnership for MSPs, MSSPs, and Enterprises include:

Comprehensive Coverage: Vijilan’s managed Network Detection and Response services, now powered by the Corelight’ Open NDR technology, provide complete visibility and protection across on- premises and cloud environments, enabling a holistic security strategy.
24/7 Monitoring and Rapid Response: With continuous monitoring and dedicated incident response teams, Vijilan ensures that any suspicious activity is swiftly identified and neutralized, minimizing potential damage.
Scalable Security Solutions: This partnership enables Vijilan to offer scalable, customizable security solutions that adapt to the evolving needs of organizations of all sizes
Strengthening the Security Stack: Incorporating NDR into a security stack enhances an organization’s overall security posture by providing critical insights into network activity, allowing for quicker identification of threats and better alignment with compliance requirements.

About Vijilan Security

Vijilan Security provides Managed Security Services to MSPs, MSSPs, and enterprises, focusing on detection, response, and containment action across all critical assets. Committed to innovation, scalability, and comprehensive coverage, Vijilan is dedicated to helping organizations protect their networks, devices, users, applications, data, and cloud services from cyber threats.

For more information, please visit Vijilan Security.

Media Contact
Company Name: Vijilan
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://vijilan.com/